Wall Street ends higher with help from tech, energy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
bluebird bio (BLUE) Prices 3.24M Share Common Offering at $185/Sh
December 13, 2017 5:44 AM ESTbluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer, today announced the pricing of an underwritten public offering of 3,243,244 shares of its common stock at a public offering price of $185 per share,... More
UPDATE: Celgene (CELG) PT Raised to $110 at Wells Fargo on 'bb2121 and Next-Gen CelMods' Updates at ASH Meetings
December 12, 2017 8:11 AM EST(Updated - December 12, 2017 8:12 AM EST)
Wells Fargo raised its price target on Celgene (NASDAQ: CELG) to $110.00 (from $101.00) while maintaining a Market Perform rating, following meetings at the American Society of Hematology.
Analyst Birchenough notes a positive outlook on the shares, following the... More
bluebird bio (BLUE) PT Raised to $225 at Wedbush
December 11, 2017 1:29 PM ESTWedbush raised its price target on bluebird bio (NASDAQ: BLUE) to $225.00 (from $174.00) while maintaining an Outperform rating after the company reported positive data in all three reported clinical programs.
"Early Group C data for sickle cell disease at 30 days were encouraging, and five... More
bluebird bio (BLUE) PT Raised to $223 at SunTrust Robinson Humphrey
December 11, 2017 8:53 AM ESTSunTrust Robinson Humphrey analyst Edward Nash raised his price target on bluebird bio (NASDAQ: BLUE) to $223.00 (from $163.00) while maintaining a Buy rating.
Nash cited the "robust durability data across all programs" presented at ASH.
"We believe the new process... More
